Company intelligence / Profile preview

Nitric Oxide Innovations, LLC

Houston, Texas, United Statesn1o1.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Nitric Oxide Innovations, LLC develops nitric oxide-based therapeutics targeting diseases associated with nitric oxide deficiency. Their lead program "NOviricid," a nitric oxide-releasing lozenge, has advanced to FDA-cleared clinical trials for COVID‑19 in high-risk populations. Early results show rapid improvement in blood oxygenation and symptoms with an excellent safety profile. The company also pursues programs in cardiovascular disease and wound care.

Therapeutic areas: CardiovascularDermatologyInfectious Diseases
Modalities: small molecules (nitric oxide releasing drugs/lozenges)topical therapeuticsoral formulations
Industry: Biotech

Drug pipeline

1 asset

nitric oxide oral formulation

Phase 1

Indications: COVID-19

Beyond the preview

Go deeper on Nitric Oxide Innovations, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nitric Oxide Innovations, LLC.

Explore the full profile